Company Overview and News
Creso Pharma Ltd (ASX:CPH) and Virbac SA (EPA:VIRP) have launched Anibidiol®, a hemp‐based complementary animal feed product in Switzerland.
According to a latest study by Future Market Insights (FMI), the global farm animal drug market is projected to grow at over 6% CAGR during the period 2017-2027. Increased production of anti-infectives and penetration of parasiticides production in Latin America is expected to offer growth opportunities to players in this market.
Persistence Market Research (PMR) delivers key insights on the global animal parasiticides market in its published report, titled "Global Market Study on Animal Parasiticides: Pharmacies and Drug Stores Distribution Channel Segment Expected to Register High Revenue Growth Through 2026." In terms of revenue, the global animal parasiticides market is estimated to register a promising CAGR of 5.9% over the forecast period, owing to numerous factors, about which PMR offers thorough insights and forecasts in this report.
The global market for bovine respiratory disease treatment features a highly consolidated competitive landscape despite the presence of a large number of regional players, observes a recent report by Transparency Market Research. Owing to the small duration of product exclusivity in the animal health care industry - about three to five years - competition from generics and over-the-counter (OTC) products is a big threat.
According to market research "Global Animal Pharmaceuticals Market Size, Share, Development, Growth and Demand Forecast to 2022 - Industry Insights by Product (Ectoparasiticides, Endoparasiticides, Anti-Inflammatories, Bronchodilators, and Others), by Animal Type (Companion Animals and Production Animals)" by P&S Market Research, the global animal pharmaceuticals market was valued at $12,614.3 million in 2015, and it is expected to grow at a CAGR of 7.
The vaccines market is expected to reach $48.03 billion by 2021 from USD 32.24 billion in 2016 at a CAGR of 8.3% driven by increasing focus on immunization programs and rising government and nongovernment funding for vaccine development while North America is expected to dominate the market globally.
Welcome to the Neogen Fourth Quarter and Year End Fiscal Year 2016 Earnings Results Conference Call. My name is Richard, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference is being recorded.
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton